logo
Fact Check: Probing claim that interstellar object is 'most likely' an alien ship heading towards Earth

Fact Check: Probing claim that interstellar object is 'most likely' an alien ship heading towards Earth

Yahoo6 days ago
Claim:
In July 2025, scientists discovered a mysterious intergalactic object that was "most likely" an alien ship that could reach Earth by November 2025.
Rating:
Rumors of an incoming alien attack invaded some social media feeds in late July 2025 after the New York Post published an article about a potential "alien probe."
While the article only said the object in question "could" be an alien probe, posts on social media described the situation with far more alarm.
For example, an Instagram post (archived) with 15,000 likes warned of an "intergalactic object" that was "most likely" an alien ship heading toward Earth. A Facebook post (archived) with 12,000 reactions sarcastically said an astrophysicist was "certain" the object was an alien ship, a claim many in the comments appeared to take at face value. An X post (archived) viewed more than 1.4 million times claimed a hostile alien ship was headed for Earth within the next three months. A TikTok video (archived) claimed that scientists said a "dangerous alien ship" was heading toward Earth and would arrive within the year.
A Snopes reader asked us to fact-check the claim.
https://www.instagram.com/p/DMj_nXZS3nX/
The claim was false. Scientists did not warn that an "intergalactic" object was "most likely" or "certainly" an alien ship heading toward Earth. The overwhelming scientific consensus was that the object was likely an interstellar comet. A few scientists published a paper analyzing a theoretical argument that it could be an alien ship, but even the paper's authors believed it to most likely be a comet.
On July 1, 2025, scientists discovered 3I/ATLAS, an interstellar object both NASA and the European Space Agency have called a comet. (An "interstellar" object is one that travels between star systems, hundreds of billions of which can be found in the Milky Way galaxy alone. An "intergalactic" object travels between galaxies, and therefore such an object by definition must originate outside the Milky Way.)
The idea that the object was an alien ship came from misunderstandings and misrepresentations of a paper titled "Is the Interstellar Object 3I/ATLAS Alien Technology?" by Harvard astrophysicist Abraham "Avi" Loeb and two researchers from the United Kingdom. But despite the title of the paper, which had not been peer-reviewed by the time it spread on social media, the paper's authors did not believe the answer to the question in the title was "yes."
"By far the most likely outcome will be that 3I/ATLAS is a completely natural interstellar object, probably a comet, and the authors await the astronomical data to support this likely origin," wrote the scientists in the paper's conclusion.
In the paper's introduction, the authors wrote that one of the reasons for analyzing the hypothesis that the comet could actually be alien technology was that "The hypothesis is an interesting exercise in its own right, and is fun to pursue, irrespective of its likely validity."
The scientists wrote that if the object was alien technology, its intentions would be either harmless, malicious or somewhere in between. Because humanity would need to do nothing if an alien craft had harmless intentions, according to the paper's authors, the possibility that it could be malicious would be of more concern. Thus, the paper assumed the object would be dangerous to humans if it were an alien ship.
After its discovery of the object, NASA said on an informational webpage that 3I/ATLAS would "remain far away" and pose "no threat to Earth."
The hypothesis that 3I/ATLAS could reach Earth by November wasn't based on the current projected path of the object. Instead, the authors of the paper estimated the arrival time based on maneuvers a theoretical alien ship could make using the gravity of the Sun or Jupiter to launch such a ship in the direction of Earth.
This was not the first time that Loeb, the Harvard astrophysicist, tried to encourage other scientists to consider the unlikely hypothesis that an interstellar object could be of artificial origin. In 2017, after the discovery of the first recorded interstellar object to enter the solar system, Loeb told The Guardian, "Most likely it is of natural origin, but because it is so peculiar, we would like to check if it has any sign of artificial origin, such as radio emissions."
"ESA Tracks Rare Interstellar Comet." European Space Agency, 3 July 2025, www.esa.int/Space_Safety/Planetary_Defence/ESA_tracks_rare_interstellar_comet. Accessed 29 July 2025.
Loeb, Abraham, et al. Is the Interstellar Object 3I/ATLAS Alien Technology? July 2025, arxiv.org/pdf/2507.12213. Accessed 29 July 2025.
"MPEC 2025-N12 : 3I/ATLAS = C/2025 N1 (ATLAS)." Minor Planet Center, International Astronomical Union, 2 July 2025, minorplanetcenter.net/mpec/K25/K25N12.html. Accessed 29 July 2025.
Sample, Ian. "Astronomers to Check Interstellar Body for Signs of Alien Technology." The Guardian, 11 Dec. 2017, www.theguardian.com/science/2017/dec/11/astronomers-to-check-interstellar-body-for-signs-of-alien-technology. Accessed 29 July 2025.
Wasser, Molly. "Comet 3I/ATLAS." NASA, 3 July 2025, science.nasa.gov/solar-system/comets/3i-atlas/. Accessed 29 July 2025.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Yahoo

timean hour ago

  • Yahoo

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

BEDFORD, Mass., August 06, 2025--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 11:30 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at About Stoke TherapeuticsStoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit View source version on Contacts Stoke Media & Investor Contacts: Dawn KalmarChief Communications Officerdkalmar@ 781-303-8302 Doug SnowDirector, Communications & Investor RelationsIR@ 508-642-6485

Dato-DXd Shows Potential in Treating Lung Adenocarcinoma
Dato-DXd Shows Potential in Treating Lung Adenocarcinoma

Medscape

timean hour ago

  • Medscape

Dato-DXd Shows Potential in Treating Lung Adenocarcinoma

This transcript has been edited for clarity. I'm Mark Kris, from Memorial Sloan Kettering, continuing a discussion about antibody-drug conjugates, or ADCs, and in this case, datopotamab deruxtecan, or Dato-DXd. This agent combines an anti-TROP2 antibody with a potent topoisomerase I inhibitor. It has had activity in a number of diseases, but the topic today is lung cancer. There has been a phase 3 randomized trial already. It's shown, compared to docetaxel, an improved rate of response by about 10% or so. It showed a small improvement in disease-free survival and about a 1-month improvement in overall survival over docetaxel. I think what this trial shows is that it clearly is an active agent, and I think it's useful to us for patients with adenocarcinoma, giving us an additional line of therapy. It would be a real judgment call when a patient needs a new line of therapy whether to give docetaxel or the Dato-DXd first. The drug is not yet approved for lung cancer but is obviously in the approval process now. The other thing noted in that phase 3 trial was that there was very limited activity. In fact, [there was] less activity than docetaxel in patients with squamous cell cancers. Clearly, that activity is largely limited to the adenocarcinoma patients, and I think that's where, if approved, it will finally be useful. The companion paper in the Journal of Clinical Oncology reports on the use of Dato-DXd in patients whose tumors have oncogenic drivers. They found a higher-than-expected response rate. It was in the twenties in an unselected population, but in the patients with EGFR mutations it was 36%, and in patients with ALK rearrangements in their tumors, it was 44%. I think this may be the place where it will be most useful. In 2025, we still don't have a therapy beyond standard chemotherapy after progression on osimertinib, and this may be a useful drug in that place. Again, it's useful in adenocarcinoma. To summarize, Dato-DXd is a drug in the regulatory approval process that clearly has activity in an unselected population of patients with adenocarcinoma. It's roughly comparable and slightly better than docetaxel. However, it's less effective than docetaxel in a squamous population. In addition, at least in other trials, it has shown some activity and perhaps even more activity in patients with drivers like EGFR or ALK .It may have some usefulness there. I think we're fortunate to have more new agents. We're fortunate to be able to make more choices to match drugs and side effects to specific patient characteristics and specific patient preferences. Once again, our job is better but it's hard. Clearly, the harder we work, the better we're going to make the course of illness for our patients.

Trump once hailed mRNA vaccines as a 'medical miracle.' Now RFK Jr. is halting advancement
Trump once hailed mRNA vaccines as a 'medical miracle.' Now RFK Jr. is halting advancement

Washington Post

timean hour ago

  • Washington Post

Trump once hailed mRNA vaccines as a 'medical miracle.' Now RFK Jr. is halting advancement

WASHINGTON — President Donald Trump hailed as a 'medical miracle' the mRNA vaccines developed to combat the deadly COVID-19 pandemic in 2020. Now, his health secretary Robert F. Kennedy Jr. , is effectively halting the vaccine technology's advancement. Kennedy announced Tuesday that the federal government is canceling $500 million worth of mRNA research development contracts, putting an end to U.S.-backed hopes for the vaccine technology to prevent future pandemics, treat cancer or prevent flu infections.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store